Who
Gerald A. Brunk
Director
Company insider
Files Form 4 as: Director and 10% owner, enGene Therapeutics; Director, MAKO Surgical.
In numbers
- Trades disclosed
- 31
- Buys
- 1
- Sells
- 0
- Bought
- $1000K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 20 Feb 2008
- Last trade
- 16 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 16 Jun 2025filed 16 Jun 2025 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 15 Jun 2024filed 18 Jun 2024 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 20 Feb 2024filed 21 Feb 2024 | ENGN enGene TherapeuticsBiotechnology | SEC FORM 4 Code A | $6.4M644,965 at $10.00 | filing |
| 20 Feb 2024filed 21 Feb 2024 | ENGN enGene TherapeuticsBiotechnology | SEC FORM 4 Code A | $1.6M155,035 at $10.00 | filing |
| 31 Oct 2023filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —114,945 | filing |
| 31 Oct 2023filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,825 | filing |
| 31 Oct 2023filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,301 | filing |
| 31 Oct 2023filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,207 | filing |
| 31 Oct 2023filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —145,603 | filing |
| 31 Oct 2023filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,673 | filing |
| 31 Oct 2023filed 2 Nov 2023 | ENGN enGene TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,341,790 | filing |
| 31 Oct 2023filed 2 Nov 2023 | ENGN enGene TherapeuticsBiotechnology | SEC FORM 4 Code A | —44,647 | filing |
| 31 Oct 2023filed 2 Nov 2023 | ENGN enGene TherapeuticsBiotechnology | SEC FORM 4 Code A | —348,686 | filing |
| 31 Oct 2023filed 2 Nov 2023 | ENGN enGene TherapeuticsBiotechnology | SEC FORM 4 Code A | —83,816 | filing |
| 31 Oct 2023filed 2 Nov 2023 | ENGN enGene TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,077,386 | filing |
| 31 Oct 2023filed 2 Nov 2023 | ENGN enGene TherapeuticsBiotechnology | SEC FORM 4 Code A | —152,974 | filing |
| 31 Oct 2008filed 3 Nov 2008 | MAKO Surgicaloption or derivative | SEC FORM 4 Code P | $3,10123,854 at $0.13 | filing |
| 31 Oct 2008filed 3 Nov 2008 | MAKO Surgicaloption or derivative | SEC FORM 4 Code P | $1,0938,404 at $0.13 | filing |
News
No headline names them, or the companies they trade most, lately.